204 related articles for article (PubMed ID: 30417093)
1. Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations.
Choi JP; Wang R; Yang X; Wang X; Wang L; Ting KK; Foley M; Cogger V; Yang Z; Liu F; Han Z; Liu R; Baell J; Zheng X
Sci Adv; 2018 Nov; 4(11):eaau0731. PubMed ID: 30417093
[TBL] [Abstract][Full Text] [Related]
2. Micro-CT Imaging Reveals Mekk3 Heterozygosity Prevents Cerebral Cavernous Malformations in Ccm2-Deficient Mice.
Choi JP; Foley M; Zhou Z; Wong WY; Gokoolparsadh N; Arthur JS; Li DY; Zheng X
PLoS One; 2016; 11(8):e0160833. PubMed ID: 27513872
[TBL] [Abstract][Full Text] [Related]
3. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.
Zhou Z; Tang AT; Wong WY; Bamezai S; Goddard LM; Shenkar R; Zhou S; Yang J; Wright AC; Foley M; Arthur JS; Whitehead KJ; Awad IA; Li DY; Zheng X; Kahn ML
Nature; 2016 Apr; 532(7597):122-6. PubMed ID: 27027284
[TBL] [Abstract][Full Text] [Related]
4. CDC42 Deletion Elicits Cerebral Vascular Malformations via Increased MEKK3-Dependent KLF4 Expression.
Castro M; Laviña B; Ando K; Álvarez-Aznar A; Abu Taha A; Brakebusch C; Dejana E; Betsholtz C; Gaengel K
Circ Res; 2019 Apr; 124(8):1240-1252. PubMed ID: 30732528
[TBL] [Abstract][Full Text] [Related]
5. The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3.
Cullere X; Plovie E; Bennett PM; MacRae CA; Mayadas TN
Proc Natl Acad Sci U S A; 2015 Nov; 112(46):14284-9. PubMed ID: 26540726
[TBL] [Abstract][Full Text] [Related]
6. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations.
Cuttano R; Rudini N; Bravi L; Corada M; Giampietro C; Papa E; Morini MF; Maddaluno L; Baeyens N; Adams RH; Jain MK; Owens GK; Schwartz M; Lampugnani MG; Dejana E
EMBO Mol Med; 2016 Jan; 8(1):6-24. PubMed ID: 26612856
[TBL] [Abstract][Full Text] [Related]
7. Somatic MAP3K3 mutation defines a subclass of cerebral cavernous malformation.
Weng J; Yang Y; Song D; Huo R; Li H; Chen Y; Nam Y; Zhou Q; Jiao Y; Fu W; Yan Z; Wang J; Xu H; Di L; Li J; Wang S; Zhao J; Wang J; Cao Y
Am J Hum Genet; 2021 May; 108(5):942-950. PubMed ID: 33891857
[TBL] [Abstract][Full Text] [Related]
8. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression.
Zhou Z; Rawnsley DR; Goddard LM; Pan W; Cao XJ; Jakus Z; Zheng H; Yang J; Arthur JS; Whitehead KJ; Li D; Zhou B; Garcia BA; Zheng X; Kahn ML
Dev Cell; 2015 Jan; 32(2):168-80. PubMed ID: 25625206
[TBL] [Abstract][Full Text] [Related]
9. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
Stockton RA; Shenkar R; Awad IA; Ginsberg MH
J Exp Med; 2010 Apr; 207(4):881-96. PubMed ID: 20308363
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism.
Ren AA; Snellings DA; Su YS; Hong CC; Castro M; Tang AT; Detter MR; Hobson N; Girard R; Romanos S; Lightle R; Moore T; Shenkar R; Benavides C; Beaman MM; Müller-Fielitz H; Chen M; Mericko P; Yang J; Sung DC; Lawton MT; Ruppert JM; Schwaninger M; Körbelin J; Potente M; Awad IA; Marchuk DA; Kahn ML
Nature; 2021 Jun; 594(7862):271-276. PubMed ID: 33910229
[TBL] [Abstract][Full Text] [Related]
11. PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.
Stamatovic SM; Sladojevic N; Keep RF; Andjelkovic AV
Acta Neuropathol; 2015 Nov; 130(5):731-50. PubMed ID: 26385474
[TBL] [Abstract][Full Text] [Related]
12. Targeting miR-27a/VE-cadherin interactions rescues cerebral cavernous malformations in mice.
Li J; Zhao Y; Choi J; Ting KK; Coleman P; Chen J; Cogger VC; Wan L; Shi Z; Moller T; Zheng X; Vadas MA; Gamble JR
PLoS Biol; 2020 Jun; 18(6):e3000734. PubMed ID: 32502201
[TBL] [Abstract][Full Text] [Related]
13. Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex.
Fisher OS; Deng H; Liu D; Zhang Y; Wei R; Deng Y; Zhang F; Louvi A; Turk BE; Boggon TJ; Su B
Nat Commun; 2015 Aug; 6():7937. PubMed ID: 26235885
[TBL] [Abstract][Full Text] [Related]
14. Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations.
Zhu Y; Wu Q; Xu JF; Miller D; Sandalcioglu IE; Zhang JM; Sure U
Neurosurg Focus; 2010 Sep; 29(3):E1. PubMed ID: 20809750
[TBL] [Abstract][Full Text] [Related]
15. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.
Lopez-Ramirez MA; Lai CC; Soliman SI; Hale P; Pham A; Estrada EJ; McCurdy S; Girard R; Verma R; Moore T; Lightle R; Hobson N; Shenkar R; Poulsen O; Haddad GG; Daneman R; Gongol B; Sun H; Lagarrigue F; Awad IA; Ginsberg MH
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34043589
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.
Lopez-Ramirez MA; Fonseca G; Zeineddine HA; Girard R; Moore T; Pham A; Cao Y; Shenkar R; de Kreuk BJ; Lagarrigue F; Lawler J; Glass CK; Awad IA; Ginsberg MH
J Exp Med; 2017 Nov; 214(11):3331-3346. PubMed ID: 28970240
[No Abstract] [Full Text] [Related]
17. Release of STK24/25 suppression on MEKK3 signaling in endothelial cells confers cerebral cavernous malformation.
Yang X; Wu ST; Gao R; Wang R; Wang Y; Dong Z; Wang L; Qi C; Wang X; Schmitz ML; Liu R; Han Z; Wang L; Zheng X
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36692953
[TBL] [Abstract][Full Text] [Related]
18. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice.
Lopez-Ramirez MA; Pham A; Girard R; Wyseure T; Hale P; Yamashita A; Koskimäki J; Polster S; Saadat L; Romero IA; Esmon CT; Lagarrigue F; Awad IA; Mosnier LO; Ginsberg MH
Blood; 2019 Jan; 133(3):193-204. PubMed ID: 30442679
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of the cerebral cavernous malformation signaling complex.
Hilder TL; Malone MH; Bencharit S; Colicelli J; Haystead TA; Johnson GL; Wu CC
J Proteome Res; 2007 Nov; 6(11):4343-55. PubMed ID: 17900104
[TBL] [Abstract][Full Text] [Related]
20. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis.
Zawistowski JS; Stalheim L; Uhlik MT; Abell AN; Ancrile BB; Johnson GL; Marchuk DA
Hum Mol Genet; 2005 Sep; 14(17):2521-31. PubMed ID: 16037064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
